Mitochondrial density and training: zone 2, biopsy data, and the nuance the popular framing skips

What the biopsy data actually show

The original muscle-biopsy literature on training and mitochondrial adaptation goes back to John Holloszy and others in the 1960s and 1970s. Those studies, mostly in rats and a smaller human cohort, established that endurance training increases mitochondrial enzyme content (citrate synthase, succinate dehydrogenase) and oxidative capacity per gram of muscle tissue .

Subsequent human work using percutaneous needle biopsy and stable-isotope tracer methods refined the picture. Mitochondrial protein synthesis rates rise after both moderate-intensity and higher-intensity endurance work. The signaling pathways (AMPK, PGC-1 alpha, mTOR) are now reasonably well mapped in the published reviews .

The zone 2 question, fairly stated

Zone 2 in the popular framing usually maps to a heart-rate range corresponding to the upper limit of fat oxidation, just below lactate threshold 1. The argument for accumulating volume in this zone is that it preferentially trains type I fiber oxidative capacity while keeping the systemic stress of training low enough to be sustainable for high weekly hours.

The honest counterpoint is that head-to-head trials of polarized (heavy-low, with little middle) vs. threshold-heavy training in trained athletes generally favor polarized training for performance outcomes. Mitochondrial enzyme content rises across both moderate-continuous and high-intensity interval protocols in randomized human studies, and the magnitude difference is not as wide as zone-2-only proponents sometimes suggest .

What actually changes mitochondrial density and function

• Total weekly aerobic time across the year, with the dose-response steepest at low base levels.
• Sufficient intensity to trigger AMPK and PGC-1 alpha signaling, which can come from moderate continuous, threshold, or interval work.
• Recovery between hard sessions, since chronic incomplete recovery blunts adaptation in human studies.
• Caloric and carbohydrate availability around hard sessions; chronic low energy availability impairs mitochondrial adaptation in published RED-S literature.

Where supplements and peptides sit

Mitochondrial-targeted compounds (MOTS-c, SS-31 / elamipretide, urolithin A) appear in the preclinical and early-translational literature. None has FDA approval for performance or longevity indications. SS-31 / elamipretide received an FDA Complete Response Letter on its mitochondrial-myopathy submission . NAD precursors (NMN, NR) are discussed elsewhere in the library.